EIT Pharma Presents Extended Phase 3 D-LIVR Trial Analyses at AASLD's The Liver Meeting® 2026

KIRKLAND, Wash., Nov. 10, 2026 /PRNewswire/ -- EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies for infectious diseases, today presented data at The Liver Meeting®, hosted by the American Association for the Study of Liver Diseases (AASLD) in Denver, Colorado. The Company presented extended analyses from its phase 3 D-LIVR trial, the largest phase 3 study to date in chronic hepatitis D (CHD), including over 400 participants in 21 countries. In comparing lonafarnib-based therapies against a placebo control, the D-LIVR study demonstrated benefit after treatment cessation and supports the continued development of lonafarnib-based therapy as a finite treatment regimen for Chronic Hepatitis D (CHD).

"We are gratified to present extended analysis from our lonafarnib trial at this year's The Liver Meeting®, a valuable forum for the hepatology community to exchange insights and advance patient care", said Dr. Leen Kawas, Chief Executive Officer of EIT Pharma. "The findings presented at The Liver Meeting® that showed durability of responses and emergence of new composite responders, reinforce our excitement around the potential of a lonafarnib-based therapy to provide patients with chronic hepatitis D a finite course of treatment with lasting benefits."

The presentation was entitled:

Durable and newly emergent treatment response during a 24-week follow-up in a finite lonafarnib treatment regimen: extended analyses from the phase 3 D-LIVR trial

• Presented by Professor Tarik Asselah, MD, PhD
• Read the presentation here

In addition to presenting within the scientific sessions at The Liver Meeting, EIT Pharma engaged more than 20 US and International Key Opinion Leaders in scientific discussion over the course of the meeting on important topics to advance care of patients living with CHD, including which clinical markers, beyond viral suppression, should be considered as important predictors of liver health outcomes.

Xue Hua, PhD, Chief Development Officer of EIT Pharma, reinforced the value of the scientific exchange, saying, "interactions with the experts within Hepatitis D, are invaluable to ensure we are developing data to demonstrate value against important markers, and ultimately help keep us focused on those attributes that are going to be meaningful for patients and are clinically relevant for the providers that care for them."

About Lonafarnib
Lonafarnib is an investigational oral therapy candidate being evaluated for the treatment of chronic hepatitis D. Lonafarnib is designed to target a key step in the hepatitis D virus cycle and is currently the only oral therapeutic candidate in late-stage clinical development for chronic hepatitis D. Lonafarnib has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for the treatment of chronic hepatitis D. The safety and efficacy of lonafarnib have not been established.

About EIT Pharma, Inc.
EIT Pharma is a biotechnology company focused on advancing therapies for infectious diseases with significant unmet medical needs. The company is developing a portfolio of programs designed to address serious infectious diseases through rigorous science, disciplined execution, and a patient-centered approach focused on translating scientific innovation into meaningful real-world impact for patients.

Forward-Looking Statements
This press release contains forward-looking statements regarding regulatory review timelines, anticipated milestones, potential product characteristics, and future development plans. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Lonafarnib is an investigational product candidate and has not been approved by the FDA. There can be no assurance that the FDA will approve the NDA or that the product will become commercially available. EIT Pharma undertakes no obligation to update forward-looking statements except as required by law.

Media Contact

Reevemark
Jacqueline Zuhse/Jamie Olensky
[email protected]
212-433-4600

SOURCE EIT Pharma